Navigation Links
Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study

Angeles, California; founder and director-emeritus of The New England Center for Headache; and clinical investigator for the Phase II study.

Merck continues to anticipate filing a New Drug Application (NDA) for MK-0974 with the U.S. Food and Drug Administration in 2009.

About migraines

Migraine headaches impact approximately 28 million Americans, primarily women. Unlike a bad headache, migraines are characterized by attacks of intense, usually one-sided, throbbing head pain that can last from four to 72 hours. The pain associated with migraine is frequently accompanied by other associated symptoms, including nausea, vomiting and increased sensitivity to light and/or sound.

About Merck

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com.

Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new i
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
4. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
5. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
(Date:3/26/2015)... , March 26, 2015 Zimmer Holdings, Inc. ... new mobile app designed to serve as a feature-rich resource ... product. For those experiencing knee pain, the ... about the causes of knee pain and helps them understand ... a safe and simple non-surgical treatment option. For those who ...
(Date:3/26/2015)... , March 26, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... received a patent acceptance notice from the Israeli patent ... to prevent or reduce tissue damage caused by an ... when cardiac vessels are opened after a blockage causing ... stroke victims. Damage can be caused to ...
(Date:3/26/2015)... InfuSystem Holdings, Inc. (NYSE MKT: INFU), a leading ... healthcare industry in the United States ... secured a new $45.0 million credit facility with JPMorgan Chase ... facility with its prior lender group.  Effective ... senior secured credit agreement comprised of a $10.0 million asset-based ...
Breaking Medicine Technology:Zimmer Launches New Patient Education And Engagement Mobile App For Gel-One Hyaluronate 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 3InfuSystem Announces New $45 Million Credit Facility At Substantially Lower Rates 2InfuSystem Announces New $45 Million Credit Facility At Substantially Lower Rates 3InfuSystem Announces New $45 Million Credit Facility At Substantially Lower Rates 4
... NEW YORK, Feb. 15, 2011 Reportlinker.com ... is available in its catalogue: ... CE countries 2011 - Comparative analysis, reimbursement ... http://www.reportlinker.com/p0395681/Generic-and-innovative-drug-market-in-CE-countries-2011---Comparative-analysis-reimbursement-policies-and-development-forecasts-for-2011-2013 ...
... 15, 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... a conference call and a live Internet webcast along with ... a.m. ET (7:00 a.m. PT) to discuss results for the ... number to participate on this call is (877) 295-5743, confirmation ...
Cached Medicine Technology:Reportlinker Adds Generic and innovative drug market in CE countries 2011 - Comparative analysis, reimbursement policies and development forecasts for 2011-2013 2Valeant Pharmaceuticals to Announce 2010 Fourth Quarter and Full Year Results on February 24, 2011 2
(Date:3/26/2015)... (PRWEB) March 26, 2015 The American College ... be on the topics of the DAOM Program as well ... Program Overview Webinar will be hosted by Dr. Carla Wilson, ... the next steps on how to prepare for the spring ... March 25, March 27, April 1 and April 3. Attendees ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 The Baruch ... new team of nationally renowned scientists to focus exclusively ... a move that nearly triples its research capacity and ... solely on hepatitis B and liver cancer in the ... Block, Jinhong Chang, Ju Tao Guo and Ying-Hsiu Su ...
(Date:3/26/2015)... 26, 2015 Visiting Nurse Association ... 18th annual gala fundraiser, Lighting the Way, Brightening the ... at The Madison Hotel in Morristown, NJ. , ... by renowned musician Rio Clemente, delightful cuisine, an extensive ... Dave Hertzel. Additionally, two prestigious awards will be presented ...
(Date:3/26/2015)... NY (PRWEB) March 26, 2015 ... its 30th “Introduction to Hyperbaric Medicine” course, which ... Medical Society (UHMS) and the National Board of ... provides the 40-hour course 4 times a year ... around the NY tri-state region; registration is available ...
(Date:3/26/2015)... March 26, 2015 On March 5, ... Matthews is out for the season with a torn ... while the Trail Blazers were competing against Dallas, and ... specialist, Izzy Silva, M.D., who has treated many ... and whether it could be prevented. , "Part ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces Upcoming Webinars 2Health News:Baruch S. Blumberg Institute Recruits World-Class Hepatitis B Scientists 2Health News:Baruch S. Blumberg Institute Recruits World-Class Hepatitis B Scientists 3Health News:Baruch S. Blumberg Institute Recruits World-Class Hepatitis B Scientists 4Health News:Morristown VNA Fundraiser to Honor Distinguished Community Members 2Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 2Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 3Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 4Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 2Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 3Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 4
... the U.S. Department of Agriculture found that a compound in ... compound, pterostilbene, is a potent antioxidant that could be developed ... effects than some commercial drugs that are currently used to ... cause of cancer death in the United States. ...
... discovered by researchers at Weill Cornell Medical College could prove ... ,The compound, called SS31, is able to cross the ... to stroke-related tissue damage. ,"In our experiments, we ... stroke led to a much smaller area of brain tissue ...
... specially developed proteins could make our bodies more resistant ... ,Steaks and chicken fillets laced with some ... against oxidation – oxidation is considered a major cause ... Shchepinov, a former Oxford University scientist, has found ...
... University of Wisconsin-Madison claim that they can efficiently seek ... cells//. This is very similar to the Nature's way ... ,The new tumor targeting strategy, presented today (March ... Chemical Society, cleverly harnesses one of the body's natural ...
... wisdom, in order to deal with teenage pregnancies and ... ,Improving pupil-teacher relationships and raising a teenager’s self-confidence ... will do the trick, say the researchers. In this ... newer ones such as focusing on sexual risks ,and ...
... the omega-3 fatty acids docosahexaenoic acid (DHA) successfully reduced ... trial, backing up previous results with higher doses. // ... which is likely to be of clinical significance with ... subjects," wrote lead author Hannah Theobald from King's College ...
Cached Medicine News:Health News:Eat Berries, Prevent Colon Cancer 2Health News:Eat Berries, Prevent Colon Cancer 3Health News:Antioxidant Molecule Could Help Minimize Stroke-Linked Brain Damage 2Health News:Tumors Targeted Naturally 2Health News:Tumors Targeted Naturally 3Health News:'School Sermons' Need a Comeback 2Health News:Low-dose Omega-3 Linked to Lower Blood Pressure 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: